Treatment of ESBL Urinary Tract Infections
Introduction to Guideline-Recommended Treatment Options
- The American Urological Association recommends oral fosfomycin (3g single dose, may repeat in 3 days) as first-line therapy for uncomplicated ESBL cystitis, showing >95% susceptibility against ESBL-producing E. coli 3
- The Infectious Diseases Society of America recommends nitrofurantoin (100mg twice daily for 5-7 days) for uncomplicated ESBL cystitis, demonstrating >90% effectiveness against ESBL-producing E. coli, but it is NOT effective for Klebsiella species or upper UTIs 3
Guideline-Recommended Treatment Options for Complicated ESBL UTI
- The American College of Clinical Pharmacy recommends carbapenems as the first-line treatment for complicated ESBL UTI or pyelonephritis, with ertapenem 1g IV daily for stable patients, or meropenem 1g IV every 8 hours for critically ill patients 1, 2, 3
- The Society of Infectious Diseases Pharmacists recommends piperacillin-tazobactam 4.5g IV every 6 hours (extended infusion) as an alternative for ESBL-producing E. coli in hemodynamically stable patients 1
- The European Society of Clinical Microbiology and Infectious Diseases recommends intravenous fosfomycin for complicated UTI in non-critically ill patients, with high-certainty evidence 1
Critical Clinical Pitfalls to Avoid
- The Centers for Disease Control and Prevention advises against using doxycycline empirically for suspected ESBL UTI, as resistance rates are unpredictable and treatment failure can lead to progression to sepsis, which occurs in 35% of inadequately treated ESBL infections 1
- The American College of Emergency Physicians recommends against using fluoroquinolones empirically due to resistance rates of 60-93% in ESBL-producing E. coli 4, 1
- The Infectious Diseases Society of America recommends against using cephalosporins against ESBL producers, regardless of in vitro susceptibility results 1, 3